For most of history, menstrual blood has been dismissed as biological waste. But emerging research is now recasting this material as a goldmine for non-invasive diagnostics and regenerative medicine. Its potential applications are surprisingly broad, ranging from innovative cervical cancer screenings to advanced cartilage repair.
Much like saliva or blood plasma, menstrual fluid is rich with biological information. It is packed with immune cells, endometrial tissue, proteins, and genetic fragments.
Scientists are now digging into these biomarkers hoping to find ways to detect diseases early, and thus drop the use of invasive clinical procedures.
Stem cells
Researchers have recently reported that they had used menstrual blood to spot cancer early. Normally, medical workers have screened for cervical cancer using clinical check-ups that many people skip due to discomfort, cost, limited access to healthcare, and in fact plain embarrassment. As a result, screening rates remain low even in economically developed regions.
In 2025, a large population-based study in The BMJ by researchers from China offered a workaround. The team found that menstrual blood collected directly from sanitary pads could be tested for human papillomavirus DNA and precancerous lesions just as accurately as cervical swab samples collected by a clinician. Of course, the method excludes those who do not menstruate, but the fact that it offered a non-invasive, inexpensive, and suitable test that could begin from home is notable.
Menstrual blood is also gaining research focus thanks to stem cells derived from it. The groundwork for this was laid back in 2007 when a team from the U.S. and Canada successfully isolated menstrual stem cells from menstrual blood. These cells came from the endometrium, the uterine lining that breaks down and rebuilds itself on a monthly cycle without scarring — something other human tissue cannot do. The researchers believed the stem cells had something to do with that ability. In the lab, the menstrual-blood-derived stem cells readily divided and proved to be tough and versatile.
Researchers are already using them to grow uterine organoids — small functional models of the uterus located outside the body and used to study conditions like endometriosis. The stem cells could reveal traces of exposure to chemical compounds like phthalates and parabens, which was previously not possible to discern without an invasive examination.
Indeed, while bone marrow stem cells are still the gold standard for many therapies, extracting them is a gruelling process. It is painful, requires anaesthesia, and bears significant surgical risks. Menstrual-blood-derived stem cells however can be collected non-invasively, and sans the ethical baggage that often complicates stem-cell sourcing.
Future of regenerative medicine
As the science of these cells has matured, so have their applications. For instance, in 2025, a team in China studied the role they could play on Niemann-Pick disease type C1. This is a rare and devastating inherited condition that is caused by cholesterol and lipids build-up inside cells, leading to rapid neurological decline, loss of motor function, and dementia. The study found that menstrual-blood-derived stem cells could significantly lower neuroinflammation and cell death in experimental models of the disease. The work is still in its early stages, but for a condition whose therapeutic options are currently limited to drugs easing the clinical symptoms, a potential new advance is welcome.
A 2023 study by Iranian researchers showed that when these cells were delivered alongside their conditioned medium — the nutrient-rich fluid they had been cultured with — they helped accelerate heart recovery in rat models after a heart attack.
In hepatology, menstrual-blood-derived stem cells have been found to suppress the specific liver cells responsible for scarring and fibrosis. Because they naturally migrate towards areas of inflammation and cancer, researchers are also exploring engineering these cells to deliver therapeutic genes directly to a tumour site, sparing the rest of the body from the toxic side effects of chemotherapy.
Many experts increasingly believe extracellular vesicles (EVs) are the future of regenerative medicine. They are easier to standardise than whole stem cells — which are complete, living biological units that can divide and adapt within the body, but vary significantly from one batch to another. They also carry risks of becoming unintended tissue types. Because EVs are not whole cells, but rather clumps of proteins, lipids, RNA, and signalling molecules enclosed by membranes secreted from the parent cell, they can’t divide or differentiate into other tissues. This makes them safer, more stable alternatives and less likely to trigger immune rejection, can be engineered to evade immune detection, and can be frozen and stored just like conventional biological drugs.
Menstrual-blood-derived stem cells can be made to release these EVs when cultured in specific conditions in the lab, such as hypoxia (low oxygen) or by adding inflammatory cytokines.
Ordinary challenges
In a notable study published in Scientific Reports in February, a team from Lithuania isolated EVs from healthy donors and introduced them to human cartilage cells taken from patients who had undergone joint surgery. Within hours, the cartilage cells had absorbed the EVs and produced a new extracellular matrix, the scaffolding of healthy joints. When the team simulated joint inflammation, the vesicles reduced the release of markers associated with cartilage degradation.
Since osteoarthritis disproportionately affects women, the researchers also tracked hormone receptors. Specifically, when they examined how EVs affected receptors in the joint tissue, they found that the EVs had increased the expression of the progesterone receptor in cartilage cells, potentially restoring a hormonal signalling pathway that tends to deteriorate in women following menopause.
While most current treatments for osteoarthritis mask the pain, these findings suggest a way to actually slow or reverse the damage. Even though the research is nascent, if the findings hold up in future trials, any benefits will matter considering the number of people living with this condition, estimated to be 595 million worldwide in 2020.
Some significant hurdles remain as well. Scientists do not yet know how long these cells will survive once they are introduced into the body. There is no long-term human safety data— partly because there are no reliable markers to track the cells once they are inside a patient. Producing consistent, high-quality batches also remains a challenge, since no standardised benchmarks exist to verify the cells before use. The cells must themselves behave differently depending on the donor, varying with age, hormonal status, contraceptive history, and the conditions in which the cells were grown in the lab.
Then again, these are ordinary challenges of early-stage biomedical research rather than reasons to dismiss what has already been found.
Manjeera Gowravaram has a PhD in RNA biochemistry and works as a freelance science writer.
Published – September 10, 2026 09:00 am IST
